|
TCMBANKIN001366 |
sterol |
|
C17H28O |
248.4 g/mol |
C1CC2CCC3C4CCC(CC4CCC3C2C1)O |
|
TCMBANKIN029162 |
18beta-glycyrrhetinic acid |
AJ-72559; Rhetinic Acid; C02283; GLYCYRRHETINIC ACID; 18-beta-Glycyrrhetinic acid; 1449-05-4; Glycyrrhetic acid; Hidermart; CHEMBL230006; SMR000058239; SR-01000721867-5; NCGC00142473-03; 18beta-Glycyrrhetinic acid, purum, >=97.0% (T); UNII-P540XA09DR; Enoxolone (Glycyrrhetin); 107420-91-7; Enoxolone, Glycyrrhetinic acid; CCRIS 3962; LMPR0106150014; 18beta-Glycyrrhetic acid; 4-10-00-03775 (Beilstein Handbook Reference); BB_NC-0599; HMS2233P23; LS-7417; (3?)-3-Hydroxy-11-oxoolean-12-en-30-oic acid; Opera_ID_1048; D0U8IF; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; NSC-35350; Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo- (8CI); AC-1925; Glycyrrhetinic acid; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxidanyl-13-oxidanylidene-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; HY-N0180; Arthrodont; Hidermart (TN); DTXSID9020669; SR-01000721867-3; MLS002207101; Enoxolona; Glycyrrhetinic acid (JAN); A-Hydroxy-11-oxoolean-12-en-30-olic acid; SR-01000721867-6; Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3beta,20beta)-; (3beta)-3-hydroxy-11-oxoolean-12-en-30-oic acid; subglycyrrhelinic acid; SCHEMBL18540; 471-53-4; Olean-12-en-30-oic acid, 3-beta-hydroxy-11-oxo-; BG01168029; FT-0082445; BX-1; Glycyrrhetin; D00156; NCGC00017244-03; 202522-39-2; 18-beta-Glycyrrhetic acid; SR-01000721867-4; Enoxolonum [INN-Latin]; SBB006496; GM-1658; Q-201057; NSC-35347; NSC 35347; (5S,8S,15S,18S,1R,2R,10R,14R,20R)-18-hydroxy-1,2,5,8,15,19,19-heptamethyl-13-o xopentacyclo[12.8.0.0<2,11>.0<5,10>.0<15,20>]docos-11-ene-8-carboxylic acid; alpha-Glycyrrhetinic acid; Tox21_112726; 130100-EP2295411A1; ZINC19203131; Biosone; D08LGJ; Bio-0549; Enoxolone; 18beta-Glycyrrhetinic acid; 3?-Hydroxy-11-oxo-18?,20?-olean-12-en-29-oic acid; Enoxolone (Glycyrrhetinic acid); 50510_FLUKA; BDBM50233538; Uralenic acid; NCGC00017244-04; P540XA09DR; 18beta-glycyrrhetic acid; C30H46O4; Jintan; Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo-; CAS-471-53-4; Tox21_200799; SR-01000721867; Enoxolone (INN); MLS001146949; MLS000028748; [(125)I] RB129; G10105_ALDRICH; (3beta,20beta)-3-Hydroxy-11-oxo-olean-12-en-29-oic acid; s2296; CCG-208506; 8055-71-8; EINECS 207-444-6; (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid; Enoxolona [INN-Spanish]; GlycyrrhetinicAcid; 18b-Glycyrrhetic acid; AC1L1UIT; 130100-EP2269977A2; KS-1262; Glycyrrhetinate; Glycyrrhetinic acid [JAN]; (3alpha,5xi,8alpha,9xi,17alpha,18xi)-3-hydroxy-11-oxoolean-12-en-29-oic acid; BC201656; Enoloxone; Enoxolone [INN:BAN:DCF]; 18 beta-glycyrrhetinic acid; 3beta-Hydroxy-11-oxo-18beta,20beta-olean-12-en-29-oic acid; enoxolone; DSSTox_RID_75722; 18 beta-Glycyrrhetintic Acid; DSSTox_CID_669; 3-Glycyrrhetinic acid; 3beta-hydroxy-11-oxoolean-12-en-29-oic acid; NCGC00181115-01; Enoxolone; STX-352; AKOS016036757; 15301-63-0; G0149; MFCD00003706; ST24038257; Enoxolone, European Pharmacopoeia (EP) Reference Standard; ST056310; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-13-keto-2,4a,6a,6b,9,9,12a-heptamethyl-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; AKOS015960428; 471G534; NCGC00258353-01; DB13089; Tox21_110804; CBW; DSSTox_GSID_20669; D0F6IV; MolPort-002-507-130; A827163; (3beta,5beta,14beta)-3-Hydroxy-11-Oxoolean-12-En-29-Oic Acid; 18beta-Glycyrrhetinic acid, 97%; CHEBI:30853; AC-8906; AN-14462; API0002854; BRN 2229654; Glyciram; 18beta-Glycyrrhetinic acid; MCULE-4676598997; 3beta-Hydroxy-11-oxoolean-12-en-30-oic acid; 3-beta-Hydroxy-11-oxoolean-12-en-30-oic acid; BG00824432; Enoxolone [BAN:DCF:INN]; CS-W020624; S00284; Enoxolonum; 299198-00-8 |
C30H46O4 |
470.68 |
CC1(C2CCC3(C(C2(CCC1O)C)C(=O)C=C4C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C |
|
TCMBANKIN030237 |
androgen |
|
C22H32O3 |
344.5 g/mol |
CCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C |
|
TCMBANKIN041161 |
abietic acid |
|
C20H30O2 |
302.5 g/mol |
CC(C)C1=CC2=CCC3C(C2CC1)(CCCC3(C)C(=O)O)C |
|
TCMBANKIN046134 |
Theaflavin 3,3'-digallate |
|
|
868.7 g/mol |
|
|
TCMBANKIN058521 |
(-)-epicatechin-3-gallate |
epicatechin-3-gallate; L-Epicatechin gallate; (-)-epicatechin gallate; (+)- Catechin gallate table; catechin gallate; 7-o-galloyl- (+) -catechin; (-)-epicatechin-3-o-gallate; (?)-epicatechin-3-o-gallate; (-)-Catechin gallate; Epicatechin gallate; (-)-Epicatechin-3-gallate; KBioSS_000794; 1257-08-5; DivK1c_006371; Spectrum2_000165; NSC 636594; KBioGR_001980; Epicatechol, 3-gallate, (-)- (8CI); [(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl] 3,4,5-trihydroxybenzoate; (−)-Epicatechin gallate; SPECTRUM210238; KBio2_003362; [(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-3-yl] 3,4,5-trihydroxybenzoate; MEGxp0_000810; KBio1_001315; (-)-Epicatechin gallate; SpecPlus_000275; BSPBio_001632; KBio2_000794; SPBio_000029; (−)-cis-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; Spectrum5_000080; SDCCGMLS-0066549.P001; Spectrum3_000246; E3893_SIAL; Spectrum_000314; Epicatechol, gallate (6CI); 3,4,5-trihydroxybenzoic acid [(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl] ester; KBio3_001132; Spectrum4_001540; Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, (2R-cis)-; Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7- dihydroxy-2H-1-benzopyran-3-yl ester, (-)-cis-; AIDS000675; 3,4,5-trihydroxybenzoic acid [(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-chromanyl] ester; KBio2_005930; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester; (−)-cis-3,3′,4′,5,7-Pentahydroxyflavane 3-gallate; AIDS-000675; catechin gallate ; catechin-3 gallate; CG; 7-o-galloyl-(+)-catechin; (-)-Epicatechin-3-O-gallate,; (-)-Epicatechin-3-gallate,; (-)-epicatechin 3-o-gallate ; SpecPlus_000275; (-)-Epicatechin gallate; KBioSS_000794; [(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-3-yl] 3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-, (2S,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester; LMPK12020090; KBio2_003362; ECG; 92587OVD8Z; 1257-08-5; 3,4,5-Trihydroxybenzoic Acid (2R,3R)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl Ester; AS-15722; Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, (2R-cis)-; UNII-92587OVD8Z; KBio3_001132; 3-Galloyl-(2R,3R)-(-)-Epicatechin; SR-05000002675; (-)-cis-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; CCG-38376; (-) epicatechin gallate; NSC636594; 3,4,5-Trihydroxy-benzoic acid 2-(3,4-dihydroxy-phenyl)-5,7-dihydroxy-chroman-3-yl ester; 3-O-Galloylepicatechin; CHEMBL36327; BDBM50153015; (-)-epicatechingallate; Epicatechin gallate; (-)-cis-3,3',4',5,7-Pentahydroxyflavane 3-gallate; AM84365; Q-200002; Epicatechol, 3-gallate, (-)-; ZINC3978503; SCHEMBL39047; C-22380; KBio1_001315; (2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; epi-Catechin 3-O-gallate; MolPort-001-740-964; (-)-epi-Catechin 3-O-gallate; DivK1c_006371; Epicatechol, gallate (6CI); (2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate; C22H18O10; Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7- dihydroxy-2H-1-benzopyran-3-yl ester, (-)-cis-; BRD-K50660797-001-01-0; NSC 636594; epicatechin-3-O-gallate; Epicatechin 3-gallate; (-)-Epicatechin-3-gallate; (-)-Epicatechin gallate,; (-)epicatechingallate; HY-N0002; epicatechin gallate, (2R-cis)-isomer; L-Epicatechin gallate; NCGC00179135-01; (-)-Epicatechin-3-O-gallate; KBio2_000794; SDCCGMLS-0066549.P001; CTK8E0233; epicatechin monogallate; CS-3761; BSPBio_001632; 3,4,5-Trihydroxy-benzoic acid (2R,3R)-2-(3,4-dihydroxy-phenyl)-5,7-dihydroxy-chroman-3-yl ester; 2.57E+87; AC-6037; AN-48941; Teatannin; Spectrum_000314; Spectrum5_000080; MEGxp0_000810; [(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; Epicatechin gallate, primary pharmaceutical reference standard; Spectrum2_000165; (2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-3-yl 3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester; Epicatechol, gallate; NP-002326; AC1L32YN; 3-Galloyl-(-)-epicatechin; (-)-Epicatechin 3-O-gallate; SPECTRUM210238; SPBio_000029; ST24033389; AC1Q5X10; Epicatechol, 3-gallate, (-)- (8CI); KBio2_005930; AJ-47571; MCULE-8110076741; Spectrum4_001540; epicatechin gallate (ECG); E0890; [(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl] 3,4,5-trihydroxybenzoate; (-)-Epicatechin gallate, >=98% (HPLC), from green tea; AKOS015965216; SR-05000002675-1; 3-Gallate(-)-Epicatechol; CHEBI:70255; KB-277863; LS-38401; LSHVYAFMTMFKBA-TZIWHRDSSA-N; (-)-cis-3,3 inverted exclamation marka,4 inverted exclamation marka,5,7-Pentahydroxyflavane 3-gallate; MFCD00075936; AX8001457; AB0017581; KBioGR_001980; Spectrum3_000246; CE0014; Q429; AIDS-231457; [(2R,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-3-yl] 3,4,5-trihydroxybenzoate; 3,4,5-trihydroxybenzoic acid [(2R,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl] ester; [(2R,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl] 3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-, (2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester; 3,4,5-trihydroxybenzoic acid [(2R,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-chromanyl] ester; AIDS231457; 3,4,5-trihydroxybenzoic acid [(2S,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl] ester; (-)-epicatechin gallate; epicatechin-3 gallate; 3,4,5-trihydroxybenzoic acid [(2S,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-chromanyl] ester; epicatechin gallate ; [(2S,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxychroman-3-yl] 3,4,5-trihydroxybenzoate; Epicatechin-3-gallate; [(2S,3S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl] 3,4,5-trihydroxybenzoate; epicatechin gallate; Benzoic acid, 3,4,5-trihydroxy-, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl ester, cis-; Epicatechin-3-galloyl ester; 863-03-6 |
C22H18O10 |
442.4 g/mol |
C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O |
|
TCMBANKIN059336 |
tauroursodeoxycholic acid |
tauroursodeoxycholicacid; ursodeoxycholicacid; ursodeoxycholic acid |
C26H45NO6S |
499.7 g/mol |
CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C |
|
TCMBANKIN059337 |
CHD;cholalic acid;cholicacid |
5beta-Cholanic acid, 3alpha,7alpha,12alpha-trihydroxy- (7CI); cholic acid; 3alpha,7alpha,12alpha-Trihydroxycholanic acid; 81-25-4 (FREE ACID); CHOLATE; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanoic acid; (3alpha,5beta,7alpha,12alpha)-3,7,12-trihydroxycholan-24-oic acid; 3alpha,7alpha,12alpha-Trihydroxy-beta-cholanic acid; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; Colalin; C9377_SIGMA; SMR000112165; 3.alpha.,7.alpha.,12.alpha.-Trihydroxy-5.beta.-cholanic acid; AIDS017669; 5.beta.-Cholan-24-oic acid, 3.alpha.,7.alpha.,12.alpha.-trihydroxy-; MLS001066422; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3alpha,5beta,7alpha,12alpha)- (9CI); AIDS-017669; Cholic acid (8CI); Cholalic acid; Cholan-24-oic acid, 3,7,12-trihydroxy-, (3-alpha,5-beta,7-alpha,12-alpha)-; Cholsaeure; C1129_SIGMA; ST024722; Spectrum5_002005; 5beta-Cholanic acid-3alpha,7alpha,12alpha-triol 5beta-Cholic acid; Cholalin; 17beta-[1-Methyl-3-carboxypropyl]etiocholane-3alpha,7alpha,12alpha-triol; 73163-53-8 (NA SALT); NSC-6135; 81-25-4; 3-&alpha,7-&alpha,12-&alpha-trihydroxy-5-&beta-cholanate; (3.alpha.,5.beta.,7.alpha.,12.alpha.)-3,7,12-Trihydroxycholan-24-oic acid sodium salt; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]valeric acid; NSC6135; CHEBI:16359; C00695; LMST04010001;cholic acid;cholic acid |
C24H40O5 |
408.57;408.6 g/mol |
CC(CCC(=O)O)C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C |
|
TCMBANKIN059926 |
(-)-gossypol |
|
C30H30O8 |
518.6 g/mol |
CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O |
|
TCMBANKIN060645 |
lovastatin |
|
C24H36O5 |
404.5 g/mol |
CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C |
滇IICP备16009434号-1 |
Dai SX Lab